International Journal of COPD podcast series

In the final episode of Season 4, Dr Surya Bhatt is here to discuss the influence of continued smoking on COPD with Dr Richard Russell. They will discuss how smoking can impact treatment decisions, how we can get our patients to stop smoking and the effects smoking can have on COPD outcomes.1–3 Dr Russell will then dive into a new publication on the impact of air quality on exacerbations during the COVID-19 lockdown,4 before highlighting what’s hot on social media. This week, the focus is on singing for lung health and how to better engage our patients!
1. Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available at: https://goldcopd.org/. Last accessed: November 2022;2. Sonnex K, et al. BMJ Open 2020;10:e037509;3. Au DH, et al. J Gen Intern Med 2009;24:457–463;4. Montiel-Lopez F, et al. ERJ Open Res 2022;8:00183–2022.
Disclosure:Dr Surya Bhatt Dr Bhatt has received grants from the National Institutes of Health, has served on advisory boards for Boehringer Ingelheim and Sanofi/Regeneron and has received continuing medical education fees from Integrity CE within the past 3 years.
Bio:
Dr Surya BhattDr Surya Bhatt is an Associate Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham (UAB), and is the Director of the UAB Lung Imaging Lab. He also serves as the Medical Director of the UAB Pulmonary Function Testing and Exercise Physiology Lab, and as the Medical Director of the UAB Telehealth and Center-based Pulmonary Rehabilitation programmes. His research focus is on developing new imaging metrics for the early diagnosis, phenotyping and precision-based therapy of COPD.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined this week by Professor James Chalmers, the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and Honorary consultant physician at Ninewells Hospital, to discuss the role of the lung microbiome in respiratory disease and the influence it may have on the management of COPD.1–3 Dr Russell will then share insights from an interesting new editorial which explores strategies implemented in the management of chronic respiratory disease in Finland from 1996–2018. 4 Finally, we delve into the social media hot topic of the week: advance care planning in COPD. Be sure to subscribe to the Medical Insider COPD podcast and never miss an episode!
1. Global Initiative for Chronic Obstructive Lung Disease 2022. Available at: here Last accessed: September 20222. Keir H, Contoli M, and Chalmers JD. Biomedicines 2021;9:1312; 3. Keir H, et al. Am J Respir Crit Care Med 2022;205:A5567;4. Tiina M, et al. Eur Respir J 2022;60:2200318
Disclosures Professor James Chalmers Professor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon. He has also received research grant support from AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Insmed and Novartis.
Bios:
Professor James Chalmers Professor James Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and an Honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult airways diseases, particularly bronchiectasis and COPD. He chaired the 2017 European Respiratory Society bronchiectasis guidelines and was also involved with 2020 Guidelines on inhaled corticosteroid use in COPD and the 2021 COVID-19 management guidelines. He is also deputy chief editor of the European Respiratory Journal and a member of the Editorial Board for the Medical Insider COPD Podcast series.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined this week by Professor David Newby, the Chair of Cardiology at the University of Edinburgh, Scotland, to discuss the overlap between COPD and cardiovascular disease in clinical practice. Listen as they explore the similarities between risk factors and patient presentation, which treatments are the most effective, and how cardiologists and respiratory physicians can work together to be the best for their patients. 1-4 Dr Russell will then highlight an interesting new paper on the associations between COPD and severe pulmonary hypertension,5 before delving into the social media hot topic of the week: mucus in the lungs.
1. Morgan AD, et al. Ther Adv Respir Dis 2018;12:1753465817750524; 2. Rabe KF, et al. Eur Respir Rev 2018;27:180057; 3. Visseren FLJ, et al. Eur Heart J 2021;42:3227–3337; 4. Rogliani P, et al. Int J Chron Obstruct Pulmon Dis 2017;12:3469–3485; 5. Dauriat G, et al. Eur Respir J 2022;60:2102897
Disclosures Professor David Newby Professor Newby reports fees from Amgen (consultancy, research projects), AstraZeneca (meetings, consultancy, lectures, research projects), Boehringer Ingelheim (meetings, lectures, research projects), Bristol Myers Squibb (meetings, consultancy, research projects), British Medical Journal (Deputy Editor of Heart), Cleerly (talks), Elsevier (books), Eli Lilly (meetings, consultancy), GE Healthcare (research projects), GlaxoSmithKline (meetings, consultancy, lectures, trial steering committee, research projects), Roche (research projects), IC Targets (research projects), Inositec (consultancy, research projects), Janssen/Johnson & Johnson (meetings, consultancy, research projects), Life Molecular Imaging (research projects), Medtronic (meetings), Nordic Pharma (research projects), Novartis (consultancy, research projects), Pfizer (meetings, consultancy, lectures, research projects), Sanofi (meetings, consultancy, lectures, research projects), Siemens (research projects), Silence Therapeutics (consultancy), Spacelabs Healthcare (research projects), Toshiba (meetings, consultancy, lectures, research projects), UCB Pharma (consultancy, data monitoring committee), Wyeth (research projects) and Zealand Pharma (consultancy).
Bios:
Professor David Newby Professor David Newby is the British Heart Foundation Duke of Edinburgh Chair of Cardiology at the University of Edinburgh, Director of the Edinburgh Clinical Research Facility, Director of the Edinburgh Imaging Facilities and a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh. He has major interests in experimental medicine, advanced imaging and clinical trials in cardiovascular disease. He has investigated the adverse cardiovascular effects of air pollution as well as the interplay between cardiovascular and respiratory disease.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

This week's guest on the Medical Insider COPD podcast is Professor Eric Bateman, a Chest Physician and Professor of Respiratory Medicine at the University of Cape Town, South Africa. Join him and Dr Richard Russell as they discuss the barriers impeding implementation of global COPD recommendations in low- and middle-income countries (LMICs) and how global guidelines might better cater to LMICs,1,2 highlighting the importance of treatment accessibility worldwide. 1,3 Dr Russell will then present important takeaways from a new and exciting publication on the use of diaphragmatic movement as a prognostic marker of COPD. 4 This will be followed by a dive into social media, where patients with COPD are discussing the safety of resuming travelling. Don’t miss out on this exciting episode of the Medical Insider COPD and remember to subscribe!
1. Hurst JR, et al. Ann Am Thorac Soc 2021;18:1269–1277;2. Global Initiative for Chronic Obstructive Lung Disease. 2022 Update. Available at: here . Last accessed: July 2022;3. Brakema EA, et al. NPJ Prim Care Respir Med 2019;29:6; 4. Mekov E, et al. Int J Chron Obstruct Pulmon Dis 2022;17:1041–1050.
Disclosures Professor Eric Bateman Eric Bateman has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Hikma Pharma, Menarini, Novartis, Regeneron and Sanofi Genzyme. He also reports consulting fees from AstraZeneca, Novartis, Regeneron and Sanofi Genzyme in the past 3 years.
Bios:
Professor Eric Bateman Professor Eric Bateman is the founder and former director of the University of Cape Town Lung Institute and former Head of the Division of Pulmonology at the University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. His primary research interests include the pharmacology and management of asthma and COPD, as well as community-based interventions to improve the care of patients. He has published more than 370 papers in international peer-reviewed journals. He is a member of both the Board and the Science Committee of the Global Initiative for Asthma and has served as President of the South African Thoracic Society. He has received numerous awards including the President’s Award from the European Thoracic Society for his global contribution to Respiratory Medicine (2012), South Africa’s National Science and Technology Forum BHP-Billiton Lifetime Award for Outstanding Contribution to Science, Engineering, Technology and Innovation (2014) and the World Lung Health Award from the American Thoracic Society (2018).
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined by Professor Antonio Anzueto in this episode of the Medical Insider COPD podcast to talk about real-world evidence and the gaps it can fill in the world of COPD research. Listen as they compare the finding from randomised controlled trials with real-world data and discuss how guidelines can be implemented in clinical practice. 1-3 Dr Russell will also highlight a new and exciting publication on the role of blood eosinophils in the development of obstructive lung disease, 4 before delving into this week’s social media hot topic of COPD fatigue. Make sure to subscribe so you don’t miss out!
1. Quint JK, et al. Adv Ther 2021;38:2249–2270;2. Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2022;3. Halpin DMG, et al. Respir Res 2016;17:120;4. Park HY, et al. Eur Respir J 2021;58:2003823.
Disclosures Dr Antonio Anzueto Dr Anzueto reports consultancy and advisory board membership fees from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva Pharma; he also reports research grants from GlaxoSmithKline. Dr Anzueto is a member of the ATS/ERS Task Force on COPD, is a member of the GOLD Scientific Committee and is a member of the Infectious Diseases Society of America/ATS Community-Acquired Pneumonia Guidelines Committee.
Bios:
Dr Antonio Anzueto Antonio R. Anzueto, MD, is a Professor of Pulmonary/Critical Care in the department of Medicine at the University of Texas Health, San Antonio. He is Chief in the Pulmonary Section, Audie L. Murphy Memorial Veterans’ Hospital Division in San Antonio, Texas, where he also serves as Medical Director of the Respiratory Therapy Department and Medical Director of the Pulmonary Function Laboratory. Dr Anzueto currently serves on the editorial board of the American Journal of Respiratory and Critical Care Medicine, the American College of Chest Physicians (CHEST) journal, the COPD journal and the Respiratory Research journal. He is affiliated with several professional organisations, including the European Respiratory Society (ERS), the American Thoracic Society (ATS) and Global Obstructive Lung Disease (GOLD) initiative.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

To begin this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Professor James Chalmers once more to delve into the topic of bronchiectasis. Specifically, they will be discussing how patients with bronchiectasis compare with patients with COPD, what treatments are the most appropriate and what the guidelines recommend. 1–3 Dr Russell also presents a new publication looking into the impact of air pollution on the respiratory health of patients with COPD, 4 and highlights what patients have been talking about on social media this week, including vaccination and exercise programmes during the COVID-19 pandemic.
1. Chalmers JD, et al. Am J Respir Crit Care Med 2018;197:1410–1420;2. Polverino E, et al. Eur Respir J 2017;50:1700629;3. Polverino E, et al. Eur Respir J 2018;51:1800328;4. Evangelopoulos D, et al. Eur Respir J 2021;58:2003432.
Disclosures Professor James ChalmersProfessor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon. He has also received research grant support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Insmed and Novartis.
Bios:
Professor James ChalmersProfessor James Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and an Honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult airways diseases, particularly bronchiectasis and COPD. He chaired the 2017 European Respiratory Society bronchiectasis guidelines, with 2020 Guidelines on inhaled corticosteroid use in COPD and the 2021 COVID-19 management guidelines. He is also deputy chief editor of the European Respiratory Journal.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

On the Medical Insider COPD Podcast this week, Dr Richard Russell is joined by Professor MeiLan Han from the University of Michigan in the United States. She will be discussing early COPD and how imaging can play a role in the diagnosis and management of COPD. 1-3 Listen as she explores the benefits of identifying COPD earlier in the course of the disease as well as in younger patients, 1,2 delving into her experience working on large long-term cohort studies. 4 Dr Russell will then present a new publication on the use of beta-blockers in patients with COPD following a myocardial infarction. 5 Stay to the end to hear Dr Russell’s thoughts on the ‘invisible epidemic’ of COPD and how we can increase awareness of the disease across the globe!
1 Labaki WW & Han MK. Ann Am Thorac Soc 2018;15:S243-S248;2 Han MK, et al. Am J Respir Crit Care Med 2020;203:414-423;3 Ash SY, et al. Radiology 2021;299:222-231;4 Lowe KE, et al. Chronic Obstrust Pulmon Dis 2019;6:384-399;5 Rasmussen DB, et al. Thorax 2020;75:928-933.
DisclosuresMeiLan Han reports personal fees from Aerogen, Altesa Biopharma, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, DevPro, GlaxoSmithKline, Integrity, Medscape, Merck, Mylan, Novartis, Polarian, Pulmonx, Regeneron, Sanofi, Teva, United Therapeutics, UpToDate and Verona. She has received either in kind research support or funds paid to the institution from AstraZeneca, Biodesix, Boehringer Ingelheim, Gala Therapeutics, NIH, Novartis, Nuvaira, Sanofi, Sunovion, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma
Bio:
Professor MeiLan HanMeiLan Han is a Professor of Internal Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at the University of Michigan Health System. She belongs to numerous professional societies including the American Thoracic Society and the European Respiratory Society. She is also a Deputy Editor for the American Journal of Respiratory and Critical Care Medicine and serves as a member of the Global Obstructive Lung Disease (GOLD) scientific committee. She is also author of a book for the lay public, Breathing Lessons, a Doctor’s Guide to Lung Health.
 
This series of podcasts are intended for healthcare professionals only.The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

This episode’s guest on the Medical Insider COPD podcast is Dr Barbara Yawn, a primary care physician and COPD clinical researcher. Join her and Dr Richard Russell as they explore the impact of breathlessness from the patient perspective, discussing physical activity, pharmacotherapy and mortality. 1-4 Dr Russell will then present the key takeaways from a new and exciting publication on the real-world impact of exacerbations on quality of life. 5 This is followed by a dive into the world of social media, where patients with COPD are discussing the use of face masks to prevent the transmission of respiratory viruses this winter.
1 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 20222 Hutchinson A, et al. Eur Respir J 2018;51:1701477;3 Waschki B, et al. Chest 2011;140:331-332;4 Watz H, et al. Eur Respir J 2014;44:1521;5 Stöber A, et al. Int J Chron Obstruct Pulmon Dis 2021;16:2637-2651
DisclosuresDr Yawn reports advisory board membership and consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Teva. She also reports research support for investigator-initiated research from GlaxoSmithKline.
Bio:
Dr Barbara YawnDr Barbara Yawn (MD MSc FAAFP) is Professor of Family and Community Health at the University of Minnesota, having retired as Director of Research at the Olmsted Medical Center and as Chief Science Officer of the COPD Foundation, USA. She is the Editor-in-Chief and Founding Editor of Respiratory Medicine Case Report Journal. Dr Yawn began her career in rural family medicine, moving on to found a research programme at the Olmsted Medical Center. She has served on numerous US national guideline panels. She has published over 400 peer-reviewed articles, several books and book chapters and is a frequent speaker at respiratory conferences in the US and internationally.
 
This series of podcasts are intended for healthcare professionals only.The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

In this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Dr Brad Drummond to discuss the topic of inhaler adherence in COPD. They will explain the factors that affect device adherence, how we can improve adherence in our patients, and the impact adherence can have on COPD outcomes. 1,2 Dr Russell will also delve into a newly released publication on necroptosis and emphysema in patients with COPD,3 before discussing the importance of talking to your patients about COVID-19 vaccination. Don’t miss out!
1 Jardim JR & Nascimento OA. Med Sci 2019;7:54;2 Restrepo RD, et al. Int J Chron Obstruct Pulmon Dis 2008;3:371–384;3 Zhe L, et al. Am J Respir Crit Care Med 2021;204:667–681.
DisclosuresDr Brad DrummondDr Drummond received compensation from Boehringer Ingelheim for development and recording of the podcast. Unrelated to the podcast, he has the following disclosures: Consulting (last 36 months): American Society of Hospital Pharmacists, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Midmark, Polarean and Teva; Research grants from Boehringer Ingelheim (external collaborative project), US Department of Defense, National Institutes of Health and Teva.
Bios:
Dr Brad DrummondDr Brad Drummond is a board-certified Pulmonary and Critical Care Physician. He is also a clinical and translational researcher whose research focus includes characterising the mechanisms for development of chronic lung disease in individuals at risk of, or with, COPD. His primary projects include a US National Heart, Lung, and Blood Institute-funded study of the role of nasal mucosal immunity and microbiome on COPD disease control. Additionally, he is the Director of the University of North Carolina Obstructive Lung Diseases Clinical and Translational Research Center, where he oversees clinical research studies supported by the National Institutes of Health and industry sponsors.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Marc Miravitlles is back to discuss mortality analyses with Dr Richard Russell.1 They will review what the guidelines recommend for initial and follow-up treatment of COPD, who should receive inhaled corticosteroids and how we should interpret mortality analyses in the COPD field.2–4 Dr Russell will then dive into a new publication on the use of FEV3/FEV6 in early airways disease identification,5 before highlighting what’s hot on social media. This week, the focus is on Lacing Up for Lungs and promoting an active and healthy lifestyle. Don’t miss out!
1 Miravitlles M, et al. Am J Respir Crit Care Med 2021;203:A2251; 2 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;3 Chalmers JD, et al. Eur Respir J 2020;55:2000351;4 Suissa S & Ariel A. Eur Respir J 2018;52:1801848;5 Yee N, et al. Chest 2021; doi: 10.1016/j.chest.2021.10.046
DisclosuresDr Marc Miravitlles has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Grifols, Menarini, Novartis, Rovi, Sandoz and Zambon. He reports consulting fees from AstraZeneca, Atriva Therapeutics, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Inhibrx, Laboratorios Esteve, Mereo Biopharma, Novartis, ONO Pharma, Palobiofarma, pH Pharma, Sanofi, SL Spin Therapeutics, Takeda, and Verona Pharma, and research grants from Grifols.   
Bio:
Dr Marc MiravitllesDr Marc Miravitlles is a Senior Researcher and Consultant at Vall d’Hebron University Hospital, Barcelona, Spain. He was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international guidelines on COPD, including the American Thoracic Society and ERS guidelines on exacerbations of COPD. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD and the coordinator of the Spanish National Guidelines for COPD
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.